Segment Information - Schedule of Reconciles Segment Direct Profit or Loss (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Segment Reporting Information [Line Items]
Total research and development	$ 12,473	$ 5,118	$ 21,807	$ 9,192
Total general and administrative	8,932	4,132	14,453	7,929
Loss from operations	(21,405)	(9,250)	(36,260)	(17,121)
QTORIN CMC [Member]
Segment Reporting Information [Line Items]
Total research and development	3,308	1,517	5,135	2,289
QTORIN Rapamycin for Microcystic LM [Member]
Segment Reporting Information [Line Items]
Total research and development	865	1,235	2,400	2,389
Qtorin Rapamycin For Angiokeratomas [Member]
Segment Reporting Information [Line Items]
Total research and development	749	0	1,201	0
QTORIN Rapamycin For Cutaneous VM [Member]
Segment Reporting Information [Line Items]
Total research and development	712	354	1,157	700
QTORIN Rapamycin for Microcystic LM - Government Grant Income [Member]
Segment Reporting Information [Line Items]
Total research and development	0	(212)	0	(339)
Salaries and Stock-based Compensation [Member]
Segment Reporting Information [Line Items]
Total research and development	3,697	1,501	6,887	2,823
Total general and administrative	5,147	1,744	8,429	3,197
Consultants [Member]
Segment Reporting Information [Line Items]
Total research and development	2,081	385	3,434	632
Total general and administrative	1,977	914	2,693	1,910
Other [Member]
Segment Reporting Information [Line Items]
Total research and development	1,061	338	1,593	698
Total general and administrative	$ 1,808	$ 1,474	$ 3,331	$ 2,822